The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left"></td><td align="center">HCT &lt; 45% <br/><svg height="10.6875" id="M8" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 56.262501 10.6875" width="56.262501" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.6875)">
<g transform="translate(72,-63.45)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑁</tspan>
<tspan style="font-size: 12.50px; " x="14.103384" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="26.143772" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="32.395271" y="0">2</tspan>
<tspan style="font-size: 12.50px; " x="38.646774" y="0">1</tspan>
</text>
</g>
</g>
</svg></td><td align="center">HCT 45–50% <br/><svg height="11.0375" id="M9" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 56.262501 11.0375" width="56.262501" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.0375)">
<g transform="translate(72,-63.17)">
<text transform="matrix(1,0,0,-1,-71.95,63.4)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑁</tspan>
<tspan style="font-size: 12.50px; " x="14.103384" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="26.143772" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="32.395271" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="38.646774" y="0">6</tspan>
</text>
</g>
</g>
</svg></td><td align="center"><svg height="10.325" id="M10" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 11.75 10.325" width="11.75" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.325)">
<g transform="translate(72,-63.74)">
<text transform="matrix(1,0,0,-1,-71.95,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
</text>
</g>
</g>
</svg> value</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">HCT %</td><td align="center">44.4 (2.3)</td><td align="center">46.5 (2.8)</td><td align="center">&lt;.0001</td></tr><tr><td align="left">White blood cells (10<sup>3</sup>/mm<sup>3</sup>)</td><td align="center">9.3 (4.7)</td><td align="center">9.3 (4.0)</td><td align="center">NS</td></tr><tr><td align="left">Platelets (10<sup>3</sup>/mm<sup>3</sup>)</td><td align="center">394.4 (169.7)</td><td align="center">424.3 (185.0)</td><td align="center">NS</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Blood cell counts in the two experimental arms of CYTO-PV <i>at the 6-month after randomization. </i>

Thrombosis

tab2

Table 2

Table 2: The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera 

Table 2 | The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera 